Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SNIPR-IV
- Development stage
- Preclinical
- Lead developer
- SNIPR Biome
- Modality
- CRISPR-Cas9 → CRISPR Systems → Programmable Nucleases → Gene Editing → Gene Therapies, Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Intravenous
01
Overview
SNIPR-IV is an investigational anti-microbial drug being developed by SNIPR Biome ApS for the treatment of complicated urinary tract infections (uUTI) and sepsis, particularly those caused by multi-drug resistant (MDR) *E. coli*. [2, 3] The drug is an intravenous formulation that utilizes a combination of bacteriophage (phage) delivery and CRISPR-Cas gene-editing technology. [3, 8] This platform, which the company refers to as CRISPR-armed phage therapy, works by using phages to deliver a CRISPR-Cas system into the target bacteria. [4] Once inside, the system is designed to recognize and cut specific DNA sequences within the bacteria, leading to a targeted killing effect while sparing other microbes. [7, 8] SNIPR-IV is part of the company's pipeline of precision medicines aimed at combating antimicrobial resistance and has reached the Investigational New Drug (IND) application stage. [1, 3]
02
Targets
bacterial dsDNA (Bacterial double-stranded DNA)Neuraminidase
Beyond the preview
Go deeper on SNIPR-IV.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SNIPR-IV.